Fig 2. Proportion at risk for reinfection among PWID who achieved HCV clearance at end of treatment (n = 30).

*Excludes one participant who was terminated early (mDOT arm); 20 participants at risk at start of mDOT and 10 participants at risk throughout Unobserved.